July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Identification and characterization of a novel protein-PEG conjugate system for long-acting delivery to the back of the eye
Author Affiliations & Notes
  • Whitney Shatz
    Protein Chemistry, Genentech, South San Francisco, California, United States
  • Nikhil Peer
    Purification Development, Genentech, South San Francisco, California, United States
  • Philip Hass
    Protein Chemistry, Genentech, South San Francisco, California, United States
  • Daniela Bumbaca
    Preclinical and Translational Pharmacokinetics, Genentech, South San Francisco, California, United States
  • Kelly Loyet
    Biochemical and Cellular Pharmacology, Genentech, South San Francisco, California, United States
  • Craig Blanchette
    Protein Chemistry, Genentech, South San Francisco, California, United States
  • Robert Kelley
    Drug Delivery, Genentech, South San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Whitney Shatz, Genentech (E); Nikhil Peer, Genentech (E); Philip Hass, Genentech (E); Daniela Bumbaca, Genentech (E); Kelly Loyet, Genentech (E); Craig Blanchette, Genentech (E); Robert Kelley, Genentech (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 243. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Whitney Shatz, Nikhil Peer, Philip Hass, Daniela Bumbaca, Kelly Loyet, Craig Blanchette, Robert Kelley; Identification and characterization of a novel protein-PEG conjugate system for long-acting delivery to the back of the eye. Invest. Ophthalmol. Vis. Sci. 2018;59(9):243. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To identify a Fab-PEG conjugate system with biophysical and pharmacokinetic attributes desirable for long-acting delivery to the back of the eye

Methods : Polyethylene glycol (PEG) structures with varied chain length, geometry and degree of branching, were selected and coupled to fragment antibody (Fab) using maleimide chemistry. Previously, it has been demonstrated that hydrodynamic radius (RH) is a key contributor of vitreal half-life (Gadkar et al, 2015, Shatz et al., 2016) and thus RH was used to rank the conjugates in vitro. Specifically, RH of each Fab-PEG conjugate was measured using size exclusion chromatography in-line with a quasi-elastic light scattering detector (SEC-QELS). The RH screen identified two potential Fab-PEG candidates, which were further differentiated using additional biophysical analyses. Once a primary candidate was selected, a large-scale Fab-PEG production scheme was developed and half-lives of the naked Fab and Fab-PEG conjugate were compared using a cynomolgous monkey pharmacokinetic (PK) ocular in vivo model.

Results : A suitable candidate for LAD back of the eye delivery was identified, demonstrating purity and process scalability, stability, and half-life extension. Indeed, intravitreal (IVT) injection of both molecules at similar Fab doses demonstrated an approximately 2-fold increase in half-life of Fab-PEG as compared to Fab alone in the cyno PK model.

Conclusions : While RH proved suitable for in vitro screening of molecules, additional biophysical analysis was necessary to differentiate the top candidates. Scale-up production of the lead candidate successfully demonstrated achievable molecular definition, even with a polydisperse molecule such as PEG. In vivo cyno PK analysis corroborated the prediction of half-life extension, further solidifying the hypothesis that a major driver of half-life extension in the vitreous is solution size.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×